CorMedix Inc. 4

Accession 0001144204-15-035560

$CRMDCIK 0001410098operating

Filed

Jun 3, 8:00 PM ET

Accepted

Jun 4, 5:03 PM ET

Size

21.8 KB

Accession

0001144204-15-035560

Form 4

Period: 2015-03-02

Director

Transactions

Sale
Common Stock, $0.001 par value per share
2015-06-04$6.48/sh−30,000$194,412→ 53,223 total
Exercise/Conversion
Stock Option (right to buy)
2015-06-02−25,000→ 5,000 total
Exercise: $0.29Exp: 2022-01-06→ Common Stock, $0.001 par value per share (30,000 underlying)
Exercise/Conversion
Stock Option (right to buy)
2015-06-02−15,000→ 15,000 total
Exercise: $0.28Exp: 2021-11-21→ Common Stock, $0.001 par value per share (30,000 underlying)
Exercise/Conversion
Common Stock, $0.001 par value per share
2015-06-02$0.28/sh+15,000$4,200→ 58,223 total
Exercise/Conversion
Common Stock, $0.001 par value per share
2015-06-02$0.29/sh+25,000$7,250→ 83,223 total

Holdings

Stock Option (right to buy)
Exercise: $2.02Exp: 2024-01-09→ Common Stock, $0.001 par value per share (30,000 underlying)
30,000
Stock Option (right to buy)
Exercise: $2.02Exp: 2024-01-09→ Common Stock, $0.001 par value per share (150,000 underlying)
150,000
Stock Option (right to buy)
Exercise: $0.90Exp: 2023-03-20→ Common Stock, $0.001 par value per share (100,000 underlying)
100,000
Stock Option (right to buy)
Exercise: $0.68Exp: 2022-12-05→ Common Stock, $0.001 par value per share (125,000 underlying)
125,000
Warrant (right to purchase Common Stock)
Exercise: $0.40From: 2012-11-13Exp: 2017-11-13→ Common Stock, $0.001 par value per share (25,000 underlying)
25,000
Warrant (right to purchase Common Stock)
Exercise: $3.48Exp: 2015-04-30→ Common Stock, $0.001 par value per share (4,884 underlying)
0
Stock Option (right to buy)
Exercise: $5.62Exp: 2025-03-01→ Common Stock, $0.001 par value per share (50,000 underlying)
50,000

Footnotes (8)

[F1]These options vested 100% on January 10, 2014.
[F2]These options vest in full on the first anniversary of the date of grant.
[F3]These options vest quarterly over two years.
[F4]These options vest as follows: (a) fifty percent (50%) on the date of issuance of the CE Mark certification for Neutrolin in Europe, which occurred on July 5, 2013, and (b) fifty percent (50%) on December 31, 2013.
[F5]On November 13, 2012, the reporting person acquired in a private placement $10,000 of (a) 9% Senior Convertible Notes, convertible into shares of the Company's common stock at a conversion price of $0.35 per share, and (b) a five-year redeemable warrant to purchase common stock at an exercise price of $0.40 per share.
[F6]The options vest ratably, one-third of which will vest on each of the grant date, the first anniversary and the second anniversary thereof.
[F7]The warrants were issued as part of the Company's initial public offering in March 2010 and were exercisable beginning six months after the effective date of the Company's registration statement related thereto.
[F8]The expiration date was originally 3/24/2015 and was extended to 4/30/2015.

Documents

1 file

CorMedix Inc.

CIK 0001410098

Entity typeoperating

IncorporatedDE